Top trend #4: We’re coming to a tipping point on cancer R&D, and it may not be pretty
Cancer of the right kidney, seen on a cross-section abdominal scan BSIP/UIG, Getty
The big trend for the past 5 years in biopharma R&D has clearly focused on new cancer therapies. The whole investment scene has tilted toward oncology with a vengeance, pouring billions into all and any new cancer therapies that look like they can make a difference — or could if they were paired up with a checkpoint therapy.
My bet is that we’re nearing a tipping point, where the prospect of diminishing returns begins to restore some semblance of balance in the way cash is invested in biotech.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.